With markets bouncing between optimism and anxiety thanks to interest-rate uncertainty and questions around the strength of the global tech rally, it is easy to forget one simple truth.
That is that long-term investors don't need perfect conditions, they just need great businesses.
And right now, the ASX is home to a handful of high-quality growth stars that continue to deliver through cycles, build global scale, and strengthen their competitive advantages year after year.
These aren't speculative punts, they are proven, profitable, long-run compounders with enormous addressable markets.
If I had to pick three ASX growth shares to back for the next five years, these would be at the top of my list.
Image source: Getty Images
Life360 Inc. (ASX: 360)
Life360 has quietly become one of Australia's most impressive global tech success stories. Its family safety app now reaches 91.6 million monthly active users, up 19% year on year, and its subscriber base continues to surge, with 2.7 million paying circles after adding a record 170,000 in the last quarter.
The company's revenue momentum is equally impressive. In the third quarter of FY 2025, Life360 delivered US$124.5 million in total revenue. This was up 34% year on year, with subscription revenue rising at the same pace.
In addition, its adjusted EBITDA jumped 174% to US$24.5 million, while operating cash flow surged 319% to US$26.4 million. Annualised monthly revenue last stood at US$446.7 million, reflecting the growing value of its subscriber ecosystem.
With a massive global addressable market, new product opportunities, and US$457.2 million in cash, Life360 looks exceptionally well placed for another five years of strong, scalable growth.
Pro Medicus Ltd (ASX: PME)
Another ASX growth share that I would buy is Pro Medicus. Its Visage imaging platform has become the go-to choice for major hospitals and radiology groups across the United States, which is the most lucrative healthcare market in the world. Every new contract improves long-term revenue visibility thanks to multi-year, multi-million-dollar deals that scale with usage.
The company's margins are among the highest on the ASX, and its capital-light model means much of its revenue flows straight through to profit and cash.
With radiology workloads rising, radiologist shortages, and hospitals under pressure to do more with less, Pro Medicus is positioned at the heart of a long-term digital transformation.
WiseTech Global Ltd (ASX: WTC)
Finally, WiseTech is a third ASX growth share I would buy. Its CargoWise platform is now used by many of the world's largest freight forwarders and logistics groups, managing everything from international shipping to customs processes.
As supply chains become more complex and companies push for efficiency, automation, and transparency, WiseTech's role becomes increasingly essential.
The company continues to expand globally through both organic growth and strategic acquisitions, adding new capabilities in areas such as customs software, compliance, and logistics optimisation. Its recurring revenue model, sticky customer relationships, and high margins give it the kind of long-term compounding profile growth investors love.
Over a five-year horizon, I believe WiseTech will be significantly larger than it is today.
